GlassScriptPhysician profile
Nicholas A Barber
NPI 1508033465
$1,225.91
in general payments reported to CMS, 2019-2025
26 companies · $403 in 2025
The $403 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.78 · 2020: $43.03 · 2021: $53.02 · 2022: $135 · 2023: $344 · 2024: $234 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $877 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $876.52 |
| Education | $103.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $181.47 | 2023-2025 | Enhertu, Injectafer, Vanflyta |
| Astellas Pharma US INC | $177.73 | 2021-2025 | Xospata, Padcev |
| Merck Sharp & Dohme LLC | $107.87 | 2022-2025 | Lynparza, Keytruda |
| Novartis Pharmaceuticals Corporation | $106.69 | 2020-2025 | |
| Aveo Pharmaceuticals, INC. | $68.06 | 2023-2025 | Fotivda |
| Genzyme Corporation | $65.82 | 2020-2023 | |
| Janssen Biotech, INC. | $48.00 | 2022-2023 | Darzalex |
| Glaxosmithkline, LLC. | $46.31 | 2022-2025 | Ojjaara |
| Pfizer INC. | $43.79 | 2022-2025 | |
| Adaptive Biotechnologies Corporation | $37.92 | 2023-2025 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $34.39 | 2023 | Libtayo |
| Amgen INC. | $32.72 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $32.59 | 2020-2024 | |
| Tempus Ai, INC | $30.57 | 2025 | Xt Cdx |
| Astrazeneca Pharmaceuticals LP | $26.57 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $25.56 | 2023 | Reblozyl |
| Agios Pharmaceuticals, INC. | $19.12 | 2022 | |
| Tersera Therapeutics LLC | $18.52 | 2022 | |
| Abbvie INC. | $18.14 | 2025 | |
| Acrotech Biopharma INC. | $18.08 | 2024 | Beleodaq |
| Ipsen Biopharmaceuticals, INC | $16.23 | 2023 | Tazverik, Onivyde |
| Pharmacyclics LLC, An Abbvie Company | $14.93 | 2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $14.78 | 2019 | |
| Sumitomo Pharma America, INC. | $14.48 | 2025 | Orgovyx |
| Seagen INC. | $13.65 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Barber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.